| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Prion Disease Research Group, Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 B' Neurological Clinic, AHEPA University Hospital, 54124 Thessaloniki, Greece
3 Laboratory of Physical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
4 Centre for Research and Technology-Hellas, Institute of Agrobiotechnology, 57001 Thessaloniki, Greece
Correspondence
Theodoros Sklaviadis
sklaviad{at}auth.gr
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTS AND DISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTS AND DISCUSSIONREFERENCES |
|---|
). They are composed mainly, if not solely, of an abnormal isoform, designated PrPSc, of the normal host-encoded cellular PrP protein (PrPC).
Prion transmission constitutes a public-health risk, especially for surgical patients, health-care workers and hospital laboratory personnel. In the acquired prion diseases, the infectious agent enters the body either through ingestion of contaminated food or during medical treatments with contaminated biological materials or surgical tools. It is noteworthy that all forms of the human TSEs are transmissible, including the sporadic and inherited ones (Dormont, 2002). Infectivity can also be harboured in tissues of humans or animals that are either subclinically infected or in the preclinical stage of the disease. Such individuals, although carriers of the infectious agent (Hill & Collinge, 2003), display no symptoms.
Prions are unusually resistant to the conventional physical and chemical methods of decontamination commonly used to inactivate other infectious agents. Standard methods for the inactivation of TSE infectious agents used in everyday practice include treatment with bleach containing 20 g active chlorine l–1, exposure to formic acid, and boiling with 1 % SDS or 1 M sodium hydroxide (Taylor, 1999). Unfortunately, in many cases these methods have proven to be inefficient (Rutala & Weber, 2001).
Advanced oxidation processes (AOPs) comprise a group of alternative chemical treatments used for the decontamination of water and air polluted with organic compounds. The different AOPs [e.g. titanium dioxide (TiO2)/UVA photocatalysis, Fe2+/H2O2 (the Fenton system), O3/UVB] share the same chemical feature, which is the generation of free hydroxyl radicals,
.
OH (Agustina et al., 2006).
.
OH radicals are strong oxidizing agents that attack organic compounds non-selectively, leading ultimately to their mineralization. TiO2 is a non-toxic compound used widely as a pigment in food and cosmetics. It is inexpensive, non-corrosive and displays catalytic activity upon exposure to natural or artificial light (UVA). When illuminated, the TiO2 particles act as semiconductors, generating
.
OH radicals and other reactive oxygen species by electrochemical reactions conducted at the surface of the photocatalyst (Mills & Le Hunte, 1997; Agustina et al., 2006).
Here, we report results concerning the heterogeneous photocatalytic degradation of PrP and PrPSc, as well as the inactivation of an experimental scrapie infectious agent under artificial UVA illumination using TiO2 as a catalyst. One of the potential objectives of the study was the development of a scaled-up method for the elimination of TSE pathogens before their environmental release from facilities that produce large amounts of possibly contaminated waste, such as hospitals, laboratories, abattoirs or even farms. The method outlined could also be adapted for decontamination of surgical instruments and smaller medical devices. The present work does not describe an inactivation protocol for any specific application, but should be seen as a first approach, demonstrating the effectiveness of TiO2-based photocatalytic treatment in the field of prion inactivation.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTS AND DISCUSSIONREFERENCES |
|---|
) and bovine and ovine PrP were expressed in Escherichia coli cells. All of the recombinant proteins were used at a final concentration of 0.15 g l–1 in the photocatalytic treatments. PrPSc-infected brain homogenates (CJD, BSE, sheep scrapie, hamster scrapie, mouse scrapie and mouse BSE) were also treated photocatalytically with TiO2. Infectious material was used either as crude brain homogenate or after PrPSc biochemical enrichment, as described below.
Photocatalytic experiments.
TiO2 P-25 (cat. no. 23.8595.0000.26
[EC]
; Degussa) was used for all photocatalytic experiments. In the P-25 formulation, the TiO2 particles are non-porous; their anatase : rutile ratio is 3.6 : 1 and their mean surface area is 50 m2 g–1. Experiments were performed in disposable 1.5 ml plastic tubes. The reaction mixture in each tube was maintained in suspension by stirring. Irradiation was carried out by using two parallel 8 W black light/blue fluorescent tubes, mounted in standard 8 W fluorescent tube holders (TLD 8W/08; Philips). Light intensity in the region of 340–400 nm was measured by using a photometer/radiometer (PMA 2100; Solar Light). The initial light intensity used in the photocatalytic experiments was evaluated to be 6.1 mW cm–2.
In all photocatalytic treatments except those with BSA and recombinant proteins, a protease inhibitor cocktail (P2714; Sigma) was included to ensure that no protein degradation by endogenous proteases occurred. The final volume of each reaction was 50 µl, containing TiO2 diluted from an 8 g l–1 stock solution in distilled water, the indicated concentrations of H2O2 from a freshly prepared 3 % solution and the appropriate amounts of the organic load and distilled water. Samples were exposed to UVA light for 2 h (recombinant proteins, BSA) or 12 h (brain homogenates and enriched PrPSc preparations).
BSA and the recombinant prion proteins were illuminated in the presence of TiO2 (2 g l–1) and H2O2 (0.5 g l–1). After exposure to UVA light, aliquots of each sample containing the equivalent of 3 µg of each protein were electrophoresed through polyacrylamide gels and stained with Coomassie brilliant blue.
Brain homogenates (10 %, w/v) were diluted 10-fold in 50 µl of a suspension containing 4 g TiO2 l–1 and 4 g H2O2 l–1. Control homogenates without the reactants were run in parallel. After UVA exposure, the remaining proteins, if any, were precipitated with 10 vols methanol overnight at –80 °C. Precipitated proteins from each 0.5 mg brain equivalent starting sample were separated on 12 % polyacrylamide gel and stained with silver as described previously (Polymenidou et al., 2002).
Enriched PrPSc preparations were treated similarly with 4 g TiO2 l–1 and 4 g H2O2 l–1 for 12 h and proteins were precipitated with 10 vols methanol overnight at –80 °C. Pellets were resuspended in 100 µl 2.5x O'Farrell sample buffer, containing 125 mM Tris/HCI (pH 6.8), 5 % (w/v) SDS, 25 % (v/v) glycerol and 7.5 % (v/v) 2-mercaptoethanol (O'Farrell, 1975). Aliquots of 30 µl of the suspension, corresponding to 3 mg brain equivalent, were used for PrPSc detection on Western blots.
PrPSc enrichment.
PrPSc was isolated quantitatively as described previously (Polymenidou et al., 2002). Sheep, hamster and mouse scrapie samples, as well as BSE samples, were treated with proteinase K (P6556; Sigma) at a concentration of 30 µg ml–1, whilst the sporadic CJD samples were treated with 50 µg ml–1. Proteinase K digestion was performed for 1 h at 37 °C in a thermomixer with shaking at 500 r.p.m. The PrPSc-enriched material was treated photocatalytically as described above and afterwards diluted to 100 µl with 5x O'Farrell sample buffer. The equivalent of 3 mg brain was used for PrPSc detection on immunoblots.
Electrophoresis and immunoblotting.
SDS-PAGE and immunodetection of PrPSc were performed as described previously (Polymenidou et al., 2002; Sachsamanoglou et al., 2004). Blots were probed with the monoclonal anti-PrP antibody 6H4 (a generous gift from Prionics). Proteins were visualized with a CDP-Phototope Star chemiluminescence kit (New England Biolabs) following the manufacturer's instructions.
Bioassays.
Brain from hamsters in the final state of disease after inoculation with scrapie strain 263K (Kimberlin & Walker, 1977) and normal hamster brain were kindly provided by Dr Ruth Gabizon (Hadassah University, Jerusalem, Israel). Homogenates (10 %, w/v) were prepared from both scrapie and control hamster brain in cold PBS containing 10 mM Tris/HCl (pH 7.4) and 300 mM sucrose using a Polytron apparatus (Kinematica). After centrifugation at 1000 g for 5 min at 4 °C, the supernatant was aliquotted and stored at –80 °C for future use.
For preparation of treated inocula, brain homogenate was diluted fourfold prior to photocatalysis. After the photocatalytic treatment, the mixture was diluted a further 2.5 times with sterile PBS containing 1 % BSA. Aliquots of 50 µl of this material were used for each inoculation.
Forty male golden Syrian hamsters, 30–40 days old, were obtained from Charles River Laboratories. They were handled according to the regulations of the local ethics committee (reference number 13/985) in a Biosafety Level 3 containment facility.
Fifteen animals were each injected intracerebrally with 50 µl treated material, which initially contained the infectivity of 1 % (w/v) brain homogenate.
Ten matched control hamsters were also injected intracerebrally with 50 µl scrapie-infected hamster brain homogenate [1 % (w/v) homogenate prepared from a 10-fold dilution of a 10 % (w/v) homogenate with PBS plus 1 % (w/v) BSA]. Fifteen negative-control animals were injected with 1 % (w/v) normal hamster brain homogenate.
Clinical evaluation.
Two observers, blind to the identity of the inoculated homogenate, performed the clinical evaluation. After day 50 post-inoculation, hamsters were examined daily for clinical symptoms characteristic of scrapie, as described previously (Prusiner et al., 1984). The onset date of the disease was considered to be the day when at least two typical symptoms were observed. Animals were sacrificed when they were terminally ill or as otherwise stated.
Statistical analysis was carried out with a 
2 test using PRISM 4.0 software (GraphPad).
|
RESULTS AND DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTS AND DISCUSSIONREFERENCES |
|---|
).
|
, lanes 1–5).
The addition of a powerful oxidizing reagent such as H2O2 or potassium peroxydisulfate (K2S2O8) to TiO2 suspensions is a well-known procedure and in many cases leads to an increased rate of photooxidation (Poulios et al., 2003; Agustina et al., 2006), especially when the initial organic load is high. H2O2 acts as an electron scavenger, which reacts with electrons at the conduction band of the TiO2 molecule to generate additional
.
OH radicals (Parra et al., 2001), thus potentiating the effect of TiO2. However, protein oxidation promoted solely by H2O2, at the concentrations used, could not account for the observed levels of protein oxidation. Reaction mixtures containing purified recombinant proteins and H2O2 were illuminated as above. As shown in Fig. 1(b, lanes 6–10) proteins remained unaffected by this treatment.
Non-specific protein oxidation mediated by TiO2 in the presence of UVA light was confirmed in experiments in which the complex protein content of infected brain homogenates from various species was present in the photocatalytic reaction. After treatment with TiO2/H2O2, complete degradation of the proteins was achieved (Fig. 2a), as assessed by silver staining. In control reactions, the proteins appeared not to be degraded after similar exposure to UVA in the absence of the photocatalyst and H2O2. These results suggested that photocatalytic treatment can be used not only for elimination of the prion protein, but for the entire protein load.
|
) developed with high-sensitivity enhanced chemiluminescence reagent.
Bioassay
The effectiveness of the photocatalytic treatment was evaluated further by an in vivo study. TiO2-treated and untreated brain homogenates from hamsters terminally ill with scrapie strain 263K were analysed on a Western blot before the initiation of the bioassays. As expected, PrPSc could only be detected in the untreated sample. In the TiO2/H2O2-treated inoculum, no PrPSc could be detected, even after extended film-exposure times (Fig. 3a).
|
), the PrP signal arising in the untreated inoculum (500 µg brain equivalent) disappeared completely after a 1000-fold dilution containing 5 µg brain tissue.
Inoculated hamsters were examined daily for symptoms of the disease after day 50 post-inoculation. The scrapie-inoculated animals entered the clinical disease phase 69.4±4.85 days post-inoculation and the terminally ill animals were sacrificed. Twelve out of 15 hamsters inoculated with TiO2/H2O2-treated material presented some clinical symptoms about 50 days later than the positive controls (mean incubation period, 119.6±9.73 days). Interestingly, the clinical phase in those animals was significantly extended, with disease symptoms lasting for over 2 months compared with a 2 week disease course seen with the positive controls. Three hamsters injected with the TiO2/H2O2-treated inoculum were sacrificed asymptomatically at 380 days post-inoculation. Fig. 4 shows the survival curves of all three hamster groups tested. Variations were statistically significant, as assessed by a 2 test (P<0.0001).
|
Brain tissues from all animals were examined for the presence of proteinase K-resistant PrP on Western blots in order to confirm the presence of the disease. Traces of PrPSc were detectable in the brains of the three asymptomatic animals, suggesting either a preclinical state of the disease or a subclinical infection due to the low infectivity titre of the inoculum (Hill & Collinge, 2003). Hamsters belonging to the negative-control group remained asymptomatic for the time span of the experiment.
Conclusions
TiO2 photocatalytic treatment has been shown to be effective in vitro for the destruction of nucleic acid molecules (Ashikaga et al., 2000) as well as proteins. Experiments performed in our laboratory showed degradation of nucleic acids (data not shown) and purified recombinant PrPs and PrPSc. Although there is no direct evidence for nucleic acid involvement in the pathogenesis of TSEs, there are indications of interactions between prion protein and nucleic acids (Murdoch et al., 1990; Akowitz et al., 1994; Cordeiro et al., 2001; Adler et al., 2003). The fact that TiO2, in the presence of UVA light, non-specifically oxidizes and destroys organic substances including proteins and nucleic acids suggests that it would cause the indistinguishable inactivation of any kind of organic component that might also be involved in TSE pathogenesis. Additionally, TiO2 has been found to be effective against both bacteria (Bekbölet & Araz, 1996; Maness et al., 1999) and viruses (Sjogren & Sierka, 1994; Watts et al., 1995). This property can be seen as a very important secondary benefit in parallel with its use in the field of prion inactivation.
Taking into account our experimental results for the photocatalytic inactivation of the TSE pathogen, it is clear that the photocatalytic treatment of liquid waste should be evaluated further as a powerful tool for disinfection of the TSE infectious agent. The method described could also be adapted for decontamination of surgical instruments. The non-specific activity of TiO2 does not exclude inactivation of unknown organic substances that may be involved in TSE pathogenesis. Of course, protocols for specific applications will have to be optimized and validated. However, the use of a low-cost and biologically inactive catalyst and the possibility of activating it with solar light, combined with the simple equipment required for this method, can offer economically reasonable, user- and environmentally friendly solutions to the processing of prion-contaminated liquid waste.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTS AND DISCUSSIONREFERENCES |
|---|
Agustina, T. E., Ang, H. M. & Vareek, V. K. (2006). A review of synergistic effect of photocatalysis and ozonation on wastewater treatment. J Photochem Photobiol C: Photochem Rev 6, 264–273.[CrossRef]
Akowitz, A., Sklaviadis, T. & Manuelidis, L. (1994). Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob disease. Nucleic Acids Res 22, 1101–1107.
Ashikaga, T., Wada, M., Kobayashi, H., Mori, M., Katsumura, Y., Fukui, H., Kato, S., Yamaguchi, M. & Takamatsu, T. (2000). Effect of the photocatalytic activity of TiO2 on plasmid DNA. Mutat Res 466, 1–7.[Medline]
Bekbölet, M. & Araz, C. V. (1996). Inactivation of Escherichia coli by photocatalytic oxidation. Chemosphere 32, 959–965.[Medline]
Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A., Brentani, R. R., Foguel, D. & Silva, J. L. (2001). DNA converts cellular prion protein into the 
-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 276, 49400–49409.
Dormont, D. (2002). Prion diseases: pathogenesis and public health concerns. FEBS Lett 529, 17–21.[CrossRef][Medline]
Hill, A. F. & Collinge, J. (2003). Subclinical prion infection in humans and animals. Br Med Bull 66, 161–170.
Kimberlin, R. H. & Walker, C. A. (1977). Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 34, 295–304.
Maness, P.-C., Smolinski, S., Blake, D. M., Huang, Z., Wolfrum, E. J. & Jacoby, W. A. (1999). Bactericidal activity of photocatalytic TiO2 reaction: toward an understanding of its killing mechanism. Appl Environ Microbiol 65, 4094–4098.
Mills, A. & Le Hunte, S. (1997). An overview of semiconductor photocatalysis. J Photochem Photobiol A: Chem 108, 1–35.
Murdoch, G. H., Sklaviadis, T., Manuelidis, E. E. & Manuelidis, L. (1990). Potential retroviral RNAs in Creutzfeldt-Jakob disease. J Virol 64, 1477–1486.
O'Farrell, P. H. (1975). High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250, 4007–4021.
Parra, S., Malato, S., Blanco, J., Péringer, P. & Pulgarin, C. (2001). Concentrating versus non-concentrating reactors for solar photocatalytic degradation of p-nitrotoluene-o-sulfonic acid. Water Sci Technol 44, 219–227.[Medline]
Polymenidou, M., Verghese-Nikolakaki, S., Groschup, M., Chaplin, M. J., Stack, M. J., Plaitakis, A. & Sklaviadis, T. (2002). A short purification process for quantitative isolation of PrPSc from naturally occurring and experimental transmissible spongiform encephalopathies. BMC Infect Dis 2, 23.[CrossRef][Medline]
Poulios, I., Micropoulou, E., Panou, R. & Kostopoulou, E. (2003). Photooxidation of eosin Y in the presence of semiconducting oxides. Appl Catal B: Environ 41, 345–355.[CrossRef]
Prusiner, S. B. (1998). Prions. Proc Natl Acad Sci U S A 95, 13363–13383.
Prusiner, S. B., McKinley, M. P., Bolton, D. C. & 7 other authors (1984). Prions: methods for assay, purification and characterization. Methods Virol 8, 293–345.
Rutala, W. A. & Weber, D. J. (2001). Creutzfeldt-Jakob disease: recommendations for disinfection and sterilization. Clin Infect Dis 32, 1348–1356.[CrossRef][Medline]
Sachsamanoglou, M., Paspaltsis, I., Petrakis, S., Verghese-Nikolakaki, S., Panagiotidis, C. H., Voigtlander, T., Budka, H., Langeveld, J. P. M. & Sklaviadis, T. (2004). Antigenic profile of human recombinant PrP: generation and characterization of a versatile polyclonal antiserum. J Neuroimmunol 146, 22–32.[CrossRef][Medline]
Sjogren, J. C. & Sierka, R. A. (1994). Inactivation of phage MS2 by iron-aided titanium dioxide photocatalysis. Appl Environ Microbiol 60, 344–347.
Taylor, D. M. (1999). Inactivation of prions by physical and chemical means. J Hosp Infect 43, S69–S76.
Watts, R. J., Kong, S., Orr, M. P., Miller, G. C. & Henry, B. E. (1995). Photocatalytic inactivation of coliform bacteria and viruses in secondary wastewater effluent. Water Res 29, 95–100.
Received 8 December 2005;
accepted 25 May 2006.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
; n=10), hamsters inoculated with the titanium-treated material clearly showed a prolonged incubation time (
; n=15), with three hamsters showing only one symptom even at 380 days after inoculation when they were sacrificed. As expected, hamsters in the negative-control group (
; n=15), which were inoculated with normal hamster brain homogenate, remained healthy for the duration of the experiment (380 days). The inset blot shows the presence of proteinase K-resistant PrP in a hamster with early development of symptoms that received the TiO2-treated inoculum (lane 1) compared with the three asymptomatic animals from the same group (lanes 2–4). Immunoblotting was performed after PrPSc enrichment as described in Methods.